Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total revenue, net | 10,785 | 10,698 |
| Costs and operating expenses: | ||
| Cost of product revenue | 1,329 | 1,262 |
| Research and development | 66,213 | 42,857 |
| Selling and marketing | 16,577 | 14,148 |
| General and administrative | 20,006 | 16,348 |
| Total costs and operating expenses | 104,125 | 74,615 |
| Loss from operations | (93,340) | (63,917) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's R&D?
- Ocular Therapeutix (OCUL) reported R&D of $66.21M in Q1 2026.
- How has Ocular Therapeutix's R&D changed year-over-year?
- Ocular Therapeutix's R&D increased by 54.5% year-over-year, from $42.86M to $66.21M.
- What is the long-term trend for Ocular Therapeutix's R&D?
- Over 4 years (2021 to 2025), Ocular Therapeutix's R&D has grown at a 40.8% compound annual growth rate (CAGR), from $50.08M to $197.1M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ocular Therapeutix's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude